Claims for Patent: 8,394,763

Summary for Patent: 8,394,763

Title:	Cyclic undecapeptides and derivatives as multiple sclerosis therapies
Abstract:	A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of a cyclosporin compound.
Inventor(s):	Forte; Michael (Portland, OR), Bourdette; Dennis (Portland, OR), Marracci; Gail (Scappoose, OR)
Assignee:	Oregon Health & Science University (Portland, OR) The United States of America as represented by the Department of Veterans Affairs (Washington, DC) N/A (N/A)
Application Number:	12/679,778
Patent Claims:	1. A method for treating a subject with multiple sclerosis, comprising administering to the subject a therapeutically effective amount of Cyclo[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-va- lyl-(2S,3R,4R,6E)-3-hydroxy-4-methyl-2-methylamino-6-octenoyl-(2S)-2-amino- butanoyl-N-methyl-D-alanyl-N-ethyl-L-valyl-L-valyl-N-methyl-L-leucyl]. 2. The method of claim 1, wherein the multiple sclerosis comprises relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis, primary progressive multiple sclerosis, or clinically isolated syndrome. 3. The method of claim 1, wherein ameliorating a symptom of multiple sclerosis comprises decreasing axon damage. 4. The method of claim 1, wherein ameliorating a symptom of multiple sclerosis comprises repair of axon damage. 5. The method of claim 1, further comprising administering to the subject a therapeutically effective amount of a second agent for the treatment of multiple sclerosis. 6. The method of claim 5, wherein the second agent for the treatment of multiple sclerosis is selected from the group consisting of a steroid, an anti-inflammatory compound, an immunosuppressive compound, and an antioxidant. 7. The method of claim 6, wherein the second agent is beta-interferon. 8. The method of claim 6, wherein the second agent is glatiramer acetate. 9. The method of claim 6, wherein the second agent is lipoic acid. 10. The method of claim 5, wherein the second agent is a monoclonal antibody. 11. The method of claim 10, wherein the monoclonal antibody is selected from the group consisting of daclizumab, rituximab and natalizumab. 12. The method of claim 5, wherein the second agent is sanglifehrin A or a derivative of sanglifehrin A.

Details for Patent 8,394,763

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2027-09-26
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2027-09-26
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	12/10/1997		2027-09-26
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	11/23/2004		2027-09-26
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029	05/27/2016		2027-09-26